TAKEDA PHARMA A/S: Financial statements 2020
CVR: 16406899
Source: annual report 2020, Danish Business Authority
01/04/2019 – 31/03/2020
TAKEDA PHARMA A/S (CVR 16406899) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 1,569,593,000 and a net result of DKK 2,661,113,000 compared with DKK 84,680,112,000 the year before. That is a decrease of 0.1% compared with the year before. The profit margin was 169.5%. Equity in the 2020 report amounted to DKK 2,707,245,000. The solvency ratio was 71.2%. The company had 179 employees in the financial year.
- Revenue
- DKK 1,569,593,000
- Gross Profit
- DKK 3,183,667,000
- Profit/Loss
- DKK 2,661,113,000
- Equity
- DKK 2,707,245,000
- Total Assets
- DKK 3,802,420,000
- Employees
- 179
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 1.6 mia. | 3.2 mia. | 2.7 mia. | 2.7 mia. | 179 |
| 2019 | 1.6 mia. | 562.3 mio. | 84.7 mia. | 1.3 mia. | 177 |
| 2018 | 1.8 mia. | 712.1 mio. | 595.8 mio. | 100.5 mia. | 197 |
| 2017 | 1.7 mia. | 626 mio. | -102.6 mio. | 99.9 mia. | 305 |
| 2016 | 1.7 mia. | 212.5 mio. | 25.3 mia. | 100.2 mia. | 488 |
Official annual report
How creditworthy is TAKEDA PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout TAKEDA PHARMA A/S
TAKEDA PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1984. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named NYCOMED DANMARK ApS and NYCOMED DANMARK A/S. The management consists of Enor Cerimagic. The board consists of Koki Sato (chair), Enor Cerimagic, Jesper Lindahl and Malene Kelstrup. The company is owned by Takeda Pharmaceuticals International AG. The company has 79 employees (2026). In 2026, the company reported revenue of DKK 1,112,753,000 and a net result of DKK 88,641,000 compared with DKK 12,162,000 the year before. Equity in the 2026 report amounted to DKK 456,501,000.